Our mission is to develop and deliver innovative therapies that improve the lives of those affected by cancer. Led by a team with a deep understanding of the biology of cancer, we are rapidly advancing two novel therapies for people living with cancer. COSELA™ (trilaciclib) is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.
Brands: https://epg-websites.com/G1/ASCOBoothBanner/G1018-19A-ASCO-Booth-Banner-Apr2021.jpg
Show Specials
Press Releases
Products